The CHM Device is a remote monitoring software solution intended to collect and store biometric data from physiological measurement devices intended for use in the home. The CHM Device also allows for the automated transmission of the biometric data to a remote secure server via an existing mobile telecommunications and/or internet infrastructure.

The stored biometric data is accessible by clinicians for analysis and intervention. Patients can also review the stored biometric data and receive educational and motivational content from clinicians.

The CHM Device can be used as a standalone device or in conjunction with supported patient monitoring devices, such as a glucometer, weight scale, pulse oximeter, and blood pressure monitor.

The CHM Device is not intended for use in surgical rooms, intensive care units, intermediate or step-down units or emergency vehicles. It is not interpretive, nor is it intended for diagnosis or as a replacement for the oversight of healthcare professionals. It does not provide real-time or emergency monitoring.

Device Description

The CHM is a software platform for the collection and display of biometric data, primarily from externally supported patient monitoring devices, both to the patient and to the clinician. The CHM Device may also be used as a standalone device. The CHM Device uses existing Internet and telecommunications architecture (cell phones and computers) for the automated transmission of medical data to a remote secure server from where it can be viewed remotely by clinicians and patients for the purposes of storage and basic analysis. The CHM Device also provides educational and motivationalities allowing the clinician to send tasks, recommendations, surveys, and educational and motivational messages to patients.

AI/ML Overview

Here's an analysis of the provided text regarding the acceptance criteria and supporting study for the Verizon Wireless Converged Health Management Device:

1. Table of Acceptance Criteria and Reported Device Performance:

Acceptance Criteria	Reported Device Performance
Ensure changes to the software have not introduced new faults.	Regression testing was performed and demonstrated that changes to the software did not introduce new faults.
Ensure that a change to one part of the software does not affect other parts of the software.	Usability testing was performed and demonstrated that changes to one part of the software did not affect other parts.
Ensure that biometric data was transferred accurately from the Telcare and Genesis Health glucometers to the server infrastructure and into the CHM platform.	Additional verification and validation activities were performed and demonstrated accurate transfer of biometric data from Telcare and Genesis Health glucometers to the server infrastructure and into the CHM platform.
All verification and validation activities, as required by the risk analysis, were performed.	All verification and validation activities, as required by the risk analysis, were performed.

2. Sample Sizes Used for the Test Set and Data Provenance:

The document states that "regression and usability testing was performed" and "additional verification and verification activities were performed." However, specific sample sizes for a 'test set' (e.g., number of data points, number of users, number of transfers) are not explicitly mentioned.

The data provenance (country of origin of the data, retrospective or prospective) is not mentioned in the provided text.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of those Experts:

The document does not mention using experts to establish ground truth in the context of the performance data. The testing appears to be focused on software functionality and data transfer accuracy against design specifications rather than against expert interpretations of medical conditions.

4. Adjudication Method for the Test Set:

An adjudication method (e.g., 2+1, 3+1, none) is not applicable or mentioned given the nature of the testing described, which focuses on software functionality and data transfer accuracy rather than diagnostic performance requiring expert consensus.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done, and the Effect Size of How Much Human Readers Improve with AI vs. Without AI Assistance:

A Multi-Reader Multi-Case (MRMC) comparative effectiveness study was not done. The device is a "remote monitoring software solution" and not an interpretive or diagnostic AI. It collects and stores biometric data for clinicians to analyze. The document explicitly states: "It is not interpretive, nor is it intended for diagnosis or as a replacement for the oversight of healthcare professionals."

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done:

The performance evaluation described is a standalone algorithm-only performance assessment in the sense that the testing verified the software's ability to accurately transfer and handle data. There is no mention of human-in-the-loop performance measurement for the device's core functionality. The clinicians still analyze the data.

7. The Type of Ground Truth Used (Expert Consensus, Pathology, Outcomes Data, etc.):

The ground truth used for the testing appears to be the expected behavior and functional requirements of the software, specifically related to accurate data transfer and functionality after changes. This is not a "medical ground truth" established by experts for diagnostic purposes but rather an engineering and software validation ground truth. For instance, for data transfer accuracy, the ground truth would be the original data from the glucometers.

8. The Sample Size for the Training Set:

The document does not mention a training set because the device is a data collection and management platform, not a machine learning or AI algorithm that requires training on a dataset to learn patterns or make predictions.

9. How the Ground Truth for the Training Set Was Established:

As there is no training set, this question is not applicable.

Summary

{0}------------------------------------------------

FEB 1 4 2014

K134004 Page 1 of 3

510(k) SUMMARY

Verizon Wireless Converged Health Management Device

Submitter's Name, Address, Telephone Number, Contact Person and Date Prepared

Verizon Wireless One Verizon Way Basking Ridge, NJ 07920 Phone: 202-515-2454 Facsimile: 202-289-6781

Contact Person: Lolita Forbes, Assistant General Counsel - Mobile Health

December 27, 2013 Date Prepared:

Name of Device and Name/Address of Sponsor

Verizon Wireless Converged Health Management Device

Verizon Wireless One Verizon Way Basking Ridge, NJ 07920

Common or Usual Name: Telemedicine System

Classification Name: Radiofrequency Physiological Signal Transmitter and Receiver

Predicate Devices:

The Verizon Wireless Converged Health Management Device is a modification to K122458 Verizon Wireless Converged Health Management Device.

{1}------------------------------------------------

K134004 Page 2 of 3

Intended Use

The CHM Device can be used as a standalone device or in conjunction with supported patient monitoring devices, such as a glucometer, weight scale, pulse oximeter, and blood pressure monitor.

Technological Characteristics

The Verizon Wireless Converged Health Management Device may be used in conjunction with the following externally supported patient monitoring devices:

. Ideal Life Inc., Blood Pressure Cuff (K060504)
� Ideal Life Inc., Glucose Monitor Model GMM0001 (K080283)
. Ideal Life Inc. SpO2 Pulse Oximeter (K070371)

{2}------------------------------------------------

K134004 Page 3 of 3

Ideal Life Inc., Weight Scale (Class I, 510(k) Exempt) .
Ideal Life Inc. Communication Gateway Ideal Life Pod ILP (K080538) .
. Telecare Inc., Blood Glucose Monitoring System (K110571)
. Genesis Health Technologies, Blood Glucose Monitoring System (K121224)

Performance Data

As part of its software verification and validation activities, regression and usability testing was performed to ensure that the changes to the software have not introduced new faults and that a change to one part of the software does not affect other parts of the software. Additional verification and verification activities were performed to ensure that the biometric data was transferred accurately from the Telcare and Genesis Health glucometers server infrastructure into the CHM platform. All verification and validation activities, as required by the risk analysis, were performed and the results demonstrated that the predetermined acceptance criteria were met.

Substantial Equivalence

The Verizon Wireless Converged Health Management Device has the same intended Use and indications for use and its predicate, Verizon Wireless Converged Health Management Device (K122458). It also has identical technological characteristics as the predicate device. Software verification and validation testing demonstrate that the Verizon Wireless Converged Health Management Device performs as intended and that the differences between the Verizon Wireless Converged Health Management Device and its predicate do not raise new questions of safety or effectivenesss.

{3}------------------------------------------------

DEPARTMENT OF HEALTH & HUMAN SERVICES

Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with three lines representing its wings, and the text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" arranged in a circular pattern around the eagle. The text is in all caps and appears to be in a sans-serif font. The logo is black and white.

Public Health Service

Food and Drug Administration 10903 New Hamoshire Avenue Document Control Center - WO66-G609 Silver Spring, MI) 20993-002

February 14, 2014

Cellco Partnership D/b/a Verizon Wireless Ms. Lolita Forbes Assistance General Counsel One Verizon Way Basking Ridge, NJ 07920 US

Re: K134004

Trade/Device Name: Verizon Wireless Converged Health Management Device Regulation Number: 21 CFR 870.2910 Regulation Name: Radiofrequency Physiological Signal Transmitter and Receiver Regulatory Class: Class II (two) Product Code: DRG Dated: December 27, 2013 Received: December 27, 2013

Dear Ms. Lolita Forbes:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations. Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must

{4}------------------------------------------------

comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, Misbranding by reference to premarket notification (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htmfor the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Owen-Paris-S

for

Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health

{5}------------------------------------------------

K134004 Page 1 of 1

Indications for Use Statement

510(k) Number (if known):

Device Name: Verizon Wireless Converged Health Management System

Indications for Use:

The CHM Device can be used as a standalone device or in conjunction with supported patient monitoring devices, such as a glucometer, weight scale, pulse oximeter, and blood pressure monitor.

Prescription Use _____________________________________________________________________________________________________________________________________________________________ (Per 21 C.F.R. 801 Subpart D) AND/OR

Over-The-Counter Use_ (Per 21 C.F.R. 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE -- CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Page 1 of 1

Digitally signed by
Owen Faris -S
Date: 2014.02.14
11:51:21-05'00'

Regulation Number and Section

§ 870.2910 Radiofrequency physiological signal transmitter and receiver.

(a)
Identification. A radiofrequency physiological signal transmitter and receiver is a device used to condition a physiological signal so that it can be transmitted via radiofrequency from one location to another, e.g., a central monitoring station. The received signal is reconditioned by the device into its original format so that it can be displayed.(b)
Classification. Class II (performance standards).